Impact News +++ Codexis (CDXS) Q3 2026 Earnings Call Transcript (Fool) +++ CODEXIS Aktie +14,16%

CODEXIS Aktie

>CODEXIS Aktienkurs

1 EUR (TradegateBSX)

Ask: 1.01 EUR / 5000 Stück

Bid: 0.99 EUR / 5000 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CODEXIS Aktie über LYNX handeln

Intraday

1 Jahr

>CODEXIS Performance

1 Woche: -3,2%

1 Monat: -25,3%

3 Monate: -35,8%

6 Monate: -58,8%

1 Jahr: -47,3%

laufendes Jahr: -35,9%

>CODEXIS Aktie

Profil:

Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis. Codexis develops and commercializes proprietary protein engineering technologies that create tailored enzymes for pharmaceutical manufacturing, RNA synthesis, mol..
>Volltext..

Insiderhandel:

>CODEXIS Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>CODEXIS Peer Group

Gesundheit, mRNA- & RNA- Therapien/ Forschung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>CODEXIS Chart & Kurs - NASDAQ

>CODEXIS News

13.11.26 - 07:36	Codexis (CDXS) Q3 2026 Earnings Call Transcript (Fool)
	Enzyme-driven manufacturing hits 100 grams as biocatalysis returns to growth....

13.11.26 - 02:54	Codexis reiterates $72M-$76M 2026 revenue outlook while extending cash runway through 2028 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.26 - 01:45	Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
	Codexis (CDXS) delivered earnings and revenue surprises of +11.11% and +4.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...

13.11.26 - 00:24	Earnings Call: Codexis übertrifft Prognosen für Q3 2026 – Aktie springt nachbörslich an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.26 - 22:33	Codexis Q3 GAAP EPS of -$0.08, revenue of $19.26M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.11.26 - 23:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Codexis im Wert von 1208 USD (Insiderkauf)
	De, Vre Raymond - Aufsichtsrat - Tag der Transaktion: 2026-11-09...

10.11.26 - 12:01	Codexis Enters into $60 Million Term Loan Facility with Trinity Capital (GlobeNewswire EN)
	Initial drawdown of $42.5 million to refinance existing term loan Initial drawdown of $42.5 million to refinance existing term loan...

09.11.26 - 12:03

Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities (GlobeNewswire EN)

Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacy Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacy...

29.10.26 - 14:04

Codexis to Report Third Quarter 2026 Financial Results on November 12 (GlobeNewswire EN)

REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update....

15.10.26 - 00:01	Insiderhandel: Vorstand verkauft Aktien von Codexis im Wert von 8619 USD (Insiderkauf)
	Erbez, Georgia - Vorstand - Tag der Transaktion: 2026-10-12...

28.09.26 - 13:06	Codexis partners with siRNA drug innovator for enzymatic oligonucleotide synthesis (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.09.26 - 12:03	Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA (GlobeNewswire EN)
	REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform....

10.09.26 - 16:31	Codexis auf Cantor-Konferenz: Enzymatische RNA-Herstellung gewinnt an Bedeutung (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

19.08.26 - 02:00	Codexis (CDXS) Q2 2026 Earnings Call Transcript (Fool)
	Product revenue surged 78% YoY as launches drive margin expansion and extend cash runway....

14.08.26 - 19:45	Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
	Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

12.08.26 - 02:15	Codexis outlines $72M-$76M 2026 revenue as it plans ~$25M GMP facility build-out (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.26 - 01:00	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
	Codexis (CDXS) delivered earnings and revenue surprises of +23.53% and +17.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...

03.08.26 - 15:03	Codexis Appoints David Butler, PhD, to Strategic Advisory Board (GlobeNewswire EN)
	Codexis Appoints David Butler, PhD, to Strategic Advisory Board...

28.07.26 - 15:03

Codexis to Report Second Quarter 2026 Financial Results on August 11 (GlobeNewswire EN)

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2026 on Tuesday, August 11, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update....

24.07.26 - 07:54	Codexis falls 20% after pricing $25M stock offering at $1.50/share (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Um in der Gesellschaft etwas zu gelten, setzt man alles daran, so zu tun, als gelte man dort schon etwas. - François VI. Duc de La Rochefoucauld

Partner: >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram